Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATTR
Biotech
FDA frees Intellia of 1 clinical hold for CRISPR therapy
The FDA is freeing Intellia’s CRISPR therapy from one of two holds, allowing a phase 3 study to resume after a patient death was reported.
Gabrielle Masson
Jan 27, 2026 10:54am
Novo Nordisk shares mixed data behind pivotal heart disease push
Nov 11, 2025 8:32am
Patient dies after receiving Intellia's CRISPR therapy
Nov 7, 2025 5:25am
Intellia pauses phase 3 CRISPR trials after patient hospitalized
Oct 27, 2025 9:45am
Ultromics nets $55M for its AI cardiac ultrasound software
Aug 4, 2025 10:40am
Intellia stock sinks on gene therapy patient's raised enzymes
May 29, 2025 9:15am
